No Data
Stifel Maintains C4 Therapeutics(CCCC.US) With Buy Rating, Maintains Target Price $14
C4 Therapeutics Announced Its Partner Betta Pharmaceuticals Has Dosed The First Patient In The Phase 1 Clinical Trial Of CFT8919, An Orally Bioavailable Allosteric Degrader Of EGFR L858R For Non-small Cell Lung Cancer In Greater China
Express News | C4 Therapeutics Announces First Patient Dosed in Cft8919 Clinical Trial
C4 Therapeutics to Present Data From the Ongoing Phase 1/2 Trial of Cemsidomide in Multiple Myeloma and Non-Hodgkin's Lymphoma at the American Society of Hematology (ASH) Annual Meeting
Seaport Therapeutics Names Lauren White as Chief Financial Officer
Morgan Stanley Maintains C4 Therapeutics(CCCC.US) With Hold Rating, Maintains Target Price $8
No Data
No Data